What is the utility of immunotherapy in management of malignant peripheral nerve sheath tumors?
In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?
Answer from: Medical Oncologist at Academic Institution
The correct answer would be "unknown" or "TBD". Enrollment on clinical trials, even broad phase 1 trials, would be encouraged in cases where SOC therapy has failed.